Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Robert Zerbe
AddedMar 31, 2024
UpdatedMay 31, 2026
Robert Zerbe

Robert Zerbe

Board Member, Vericel

CrunchbaseLinkedIn

Robert Zerbe's Career

Vericel
Vericel

Cambridge, MA, US

Board Member· Board
Cirius Therapeutics
Cirius Therapeutics

Kalamazoo, MI, US

Board Member· Board
Edgemont Pharmaceuticals
Edgemont Pharmaceuticals

Austin, TX, US

Board Member· Board
Metabolic Solutions Development
Metabolic Solutions Development

Kalamazoo, MI, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Robert Zerbe's Career

Vericel
Vericel
Public3051989Cambridge, MA, US
Board Member· Board

Leadership at Vericel

Heidi HagenHeidi HagenBoard Member
Paul WottonPaul WottonBoard Member
Nick ColangeloNick ColangeloBoard Member
Kevin McLaughlinKevin McLaughlinBoard Member

Similar to Vericel

CelularityCelularityFlorham Park, NJ, USCell Therapiesest. 2016CelularityFlorham Park, NJ, US · est. 2016

Celularity, a US-based biotech firm, pioneers in delivering large-scale, quality allogeneic placenta-derived cellular therapies.

Public · $400M225
AthersysAthersysCleveland, OH, USStem Cell Productsest. 1995AthersysCleveland, OH, US · est. 1995

Athersys, Inc.: A US-based biotech firm developing allogeneic stem cell products for various health conditions.

Public · $208.9M83
AlphaStemAlphaStemAtlanta, GA, USCell Therapyest. 1981AlphaStemAtlanta, GA, US · est. 1981

AlphaStem pioneers in cell-based therapy for cardiovascular disease.

Angel · $86.7k32
Cirius Therapeutics
Cirius Therapeutics
Series A$49M302015Kalamazoo, MI, US
Board Member· Board

Leadership at Cirius Therapeutics

Bob BalteraBob BalteraCEO
Dennis FentonDennis FentonBoard Member
Elaine SunElaine SunBoard Member
Nilesh KumarNilesh KumarBoard Member
Dan EstesDan EstesBoard Member
Mike JandernoaMike JandernoaBoard Member
Edgemont Pharmaceuticals
Edgemont Pharmaceuticals
Series A$9.8M112015Austin, TX, US
Board Member· Board

Leadership at Edgemont Pharmaceuticals

Douglas A SaltelDouglas A SaltelFounder
Thomas KoestlerThomas KoestlerBoard Member
Metabolic Solutions Development
Metabolic Solutions Development
Series B$58.5M142011Kalamazoo, MI, US
Board Member· Board

Leadership at Metabolic Solutions Development

Stephen BenoitStephen BenoitBoard Member
Jerry ColcaJerry ColcaBoard Member
Rolf KletzienRolf KletzienBoard Member
Jerry CallahanJerry CallahanBoard Member
Mark OlesnavageMark OlesnavageBoard Member
William U ParfetWilliam U ParfetBoard Member

Similar to Metabolic Solutions Development

Cirius TherapeuticsCirius TherapeuticsKalamazoo, MI, USPharmaceuticalsest. 2015Cirius TherapeuticsKalamazoo, MI, US · est. 2015

Cirius Therapeutics: A Michigan-based pharmaceutical company specializing in insulin sensitizers.

Series A · $49M30
EndoMetabolic SolutionsEndoMetabolic SolutionsBrooklyn Park, MN, USMedical Devicesest. 2007EndoMetabolic SolutionsBrooklyn Park, MN, US · est. 2007

EndoMetabolic Solutions: Developing surgical obesity treatment devices since 2007.

Series A · $3.8M3
Restor MetabolixRestor MetabolixMarietta, GA, USDiabetic Treatments, Metabolic Treatmentsest. 2021Restor MetabolixMarietta, GA, US · est. 2021

Restor Metabolix, a Georgia-based firm, offers scientifically proven diabetic treatments and metabolic disorder solutions, focusing on insulin desensitization.

Pre-Seed · $1M17
KinDex PharmaceuticalsKinDex PharmaceuticalsSeattle, WA, USTherapeuticsest. 2009KinDex PharmaceuticalsSeattle, WA, US · est. 2009

KinDex Pharmaceuticals develops novel therapeutics for metabolic disorder treatment.

Angel · $5.8M10

Robert Zerbe's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Robert Zerbe

Shalom Z. HirschmanShalom Z. HirschmanBoard Member · Quantrx BiomedicalKevin HrusovskyKevin HrusovskyBoard Member · QuanterixPerry NisenPerry NisenBoard Member · Teva Pharmaceutical IndustriesDaniel ZurrDaniel ZurrBoard Member · Quark PharmaceuticalsThomas LinesThomas LinesBoard Member · FRS